BOSTON, March 12, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced that it will host a conference call on Thursday, March 19, 2015 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and the full year ended December 31, 2014.
Participants may access the call by dialing 844-824-7428 in the U.S. or 973-500-2177 outside the U.S. The call will also be webcast live on the Company's website at www.zafgen.com. A replay of this conference call will be available beginning at 7:30 p.m. ET on March 19, 2015 through March 26, 2015 by dialing 855-859-2056 in the U.S. or 404-537-3406 outside the U.S. Please provide Conference ID number 5923144.
About Zafgen, Inc.
Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders. Zafgen is focused on developing novel therapeutics that treat the underlying biological mechanisms through the MetAP2 pathway. Beloranib, Zafgen's lead product candidate, is a novel, first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome, or PWS, and obesity caused by hypothalamic injury, including craniopharyngioma-associated obesity; and severe obesity in the general population. Zafgen aspires to improve the lives of patients through targeted treatments and has assembled a team accomplished in bringing therapies to patients with both rare and prevalent metabolic diseases.
CONTACT: FTI Consulting Kimberly Ha Investor Relations 212-850-5612 Kimberly.Ha@fticonsulting.comSource:Zafgen, Inc.